Clinical trial
A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
NCT06584435 is registered in ClinicalTrials.gov with Tianjin Medical University Second Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
- Lead sponsor
- Tianjin Medical University Second Hospital
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- October 10, 2022
- Completion date
- November 1, 2027
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
high-risk renal cell carcinoma